The Schall Law Firm Reminds Investors of Class Action Lawsuit Against Lifecore Biomedical, Inc.

LOS ANGELES, CA / ACCESSWIRE / September 21, 2024

The Schall Law Firm, a national shareholder rights litigation firm, is reminding investors of a class action lawsuit against Lifecore Biomedical, Inc. (“Lifecore” or “the Company”) (NASDAQ:LFCR). The lawsuit alleges violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased Lifecore’s securities between October 7, 2020 and March 19, 2024, inclusive (the “Class Period”), are encouraged to contact the firm before September 27, 2024.

During the Class Period, Lifecore is accused of making false and misleading statements about its business operations and financial performance. The lawsuit claims that Lifecore failed to disclose that the Company’s manufacturing facilities did not comply with applicable regulations and did not have sufficient quality control measures in place. As a result, Lifecore’s statements about its business, operations, and prospects were materially false and misleading.

Effects on Individual Investors

Individual investors who purchased Lifecore’s securities during the Class Period may be eligible to participate in the class action lawsuit. If the lawsuit is successful, investors may be entitled to financial compensation for any losses suffered as a result of the alleged securities law violations by Lifecore. It is important for investors to contact the Schall Law Firm before the September 27, 2024 deadline to ensure their rights are protected.

Global Impact

The class action lawsuit against Lifecore Biomedical, Inc. may have wider implications for the biotechnology and healthcare industries. Investors and stakeholders in similar companies may closely follow the outcome of this case to gauge the potential impact on regulatory compliance and financial transparency within the sector. The lawsuit could also influence corporate governance practices and investor confidence in the industry as a whole.

Conclusion

Investors who purchased Lifecore Biomedical, Inc. securities are encouraged to contact the Schall Law Firm before the September 27, 2024 deadline to participate in the class action lawsuit. The outcome of this case may have significant implications for individual investors and the broader biotechnology and healthcare industries. Stay informed and protect your rights as an investor.